Literature DB >> 10553059

CD4+ CD45RB low-density cells from untreated mice prevent acute allograft rejection.

J D Davies1, E O'Connor, D Hall, T Krahl, J Trotter, N Sarvetnick.   

Abstract

In the absence of therapy that suppresses the action of the immune system, the immune response to transplantation Ags results in rapid rejection of the transplant. The most successful mechanism so far described that achieves organ-specific immunological tolerance is that which controls peripheral tolerance to self-tissue. Until now, no similarities have been documented between the peripheral response to self-Ags and the response to transplantation Ags. CD4+ cells that express a high density of CD45RB (in the mouse) and CD45RC (in the rat) on their surface have been shown to cause a number of autoimmune disorders. In contrast, autoimmunity caused by the CD45RB high-density cells is inhibited by CD4+ CD45RB cells that express a low density of CD45RB (CD45RC in the rat). In this paper we show that CD4+ CD45RB high-density cells are sufficient to cause rejection of a MHC-mismatched pancreas allograft, whereas CD4+ CD45RB low-density cells are not. Unexpectedly, the CD45RB low-density cells prevent the CD45RBhigh expressing cells from causing rejection. These data suggest that the response to foreign tissue can be controlled in the same way as the response to self-tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Allograft rejection results from a failed attempt by the immune system to protect foreign tissue.

Authors:  D S Hall; E Roberts; J Davies
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  IL-4 expression delays eosinophil-independent vasculopathy and fibrosis during allograft rejection in the mouse.

Authors:  Edda M Roberts; De Shon Hall; Sharon Ferguson; Susan Minson; Joanna D Davies
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

3.  CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism.

Authors:  Zhenhua Dai; Qi Li; Yinong Wang; Ge Gao; Lonnette S Diggs; George Tellides; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 4.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

5.  Characterisation of the T cell and dendritic cell repertoire in a murine model of mucopolysaccharidosis I (MPS I).

Authors:  Louise D Archer; Kia J Langford-Smith; William R Critchley; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2012-07-07       Impact factor: 4.982

Review 6.  Homeostatic T cell proliferation as a barrier to T cell tolerance.

Authors:  Somia P Hickman; Laurence A Turka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

7.  Specificity of CD4+CD25+ regulatory T cell function in alloimmunity.

Authors:  Alberto Sánchez-Fueyo; Sigrid Sandner; Antje Habicht; Christophe Mariat; James Kenny; Nicolas Degauque; Xin Xiao Zheng; Terry B Strom; Laurence A Turka; Mohamed H Sayegh
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

8.  CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo.

Authors:  Z Wang; J D Davies
Journal:  Int Immunopharmacol       Date:  2006-11-28       Impact factor: 4.932

Review 9.  Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.

Authors:  Louise D Archer; Kia J Langford-Smith; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

10.  The roles of IL-2 and IL-10 enhance anti-CD45RBmAb immune inhibition in allograft skin.

Authors:  Wei-Jian Guo; Hui Qi; Chun-Yan Deng; Han-Xin Zhou; Shao-Ping Deng; Fu-Rong Li
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.